Clinical Trial Update: Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the effect of liraglutide on subclinical atherosclerosis in patients with type 1 diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Subclinical Atherosclerosis
• Type 1 Diabetes Mellitus

Drugs mentioned

• liraglutide (liraglutide)

Snippet

Sponsor: David Sanchez Garcia | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED